Search Results - "Dmoszyñska, Anna"

Metformin - its potential anti-cancer and anti-aging effects by Podhorecka, Monika, Ibanez, Blanca, Dmoszyńska, Anna

“…The generally accepted mechanism of metformin's effect is stimulation of adenosine monophosphate (AMP)-activated protein kinase (AMPK). AMPK is directly…”
Get full text

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia by KANTARJIAN, Hagop M, THOMAS, Xavier G, KUO, Ching-Yuan, ORIOL, Albert, RAVANDI, Farhad, FADERL, Stefan, DELAUNAY, Jacques, LYSAK, Daniel, MINDEN, Mark, ARTHUR, Christopher, DMOSZYNSKA, Anna, WIERZBOWSKA, Agnieszka, MAZUR, Grzegorz, MAYER, Jiri, GAU, Jyh-Pyng, CHOU, Wen-Chien, BUCKSTEIN, Rena, CERMAK, Jaroslav

“…This multicenter, randomized, open-label, phase III trial compared the efficacy and safety of decitabine with treatment choice (TC) in older patients with…”
Get full text

Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia by HILLMEN, Peter, SKOTNICKI, Aleksander B, ROBAK, Tadeusz, JAKSIC, Branimir, DMOSZYNSKA, Anna, JINGYANG WU, SIRARD, Cynthia, MAYER, Jiri

“…We conducted a randomized trial to evaluate the efficacy and safety of intravenous alemtuzumab compared with chlorambucil in first-line treatment of chronic…”
Get full text

Th17/IL-17A might play a protective role in chronic lymphocytic leukemia immunity by Hus, Iwona, Bojarska-Junak, Agnieszka, Chocholska, Sylwia, Tomczak, Waldemar, Woś, Justyna, Dmoszyńska, Anna, Roliński, Jacek

“…Th17 cells, a recently discovered subset of T helper cells that secrete IL-17A, can affect the inflammation process autoimmune and cancer diseases development…”
Get full text

Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia by Robak, Tadeusz, Dmoszynska, Anna, Solal-Céligny, Philippe, Warzocha, Krzysztof, Loscertales, Javier, Catalano, John, Afanasiev, Boris V, Larratt, Loree, Geisler, Christian H, Montillo, Marco, Zyuzgin, Ilya, Ganly, Peter S, Dartigeas, Caroline, Rosta, András, Maurer, Jörg, Mendila, Myriam, Saville, M Wayne, Valente, Nancy, Wenger, Michael K, Moiseev, Sergey I

“…Rituximab, a monoclonal antibody that targets the CD20 cell surface antigen, has clinical activity in patients with non-Hodgkin's lymphoma and other…”
Get full text

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma by San Miguel, Jesús F, Schlag, Rudolf, Khuageva, Nuriet K, Dimopoulos, Meletios A, Shpilberg, Ofer, Kropff, Martin, Spicka, Ivan, Petrucci, Maria T, Palumbo, Antonio, Samoilova, Olga S, Dmoszynska, Anna, Abdulkadyrov, Kudrat M, Schots, Rik, Jiang, Bin, Mateos, Maria-Victoria, Anderson, Kenneth C, Esseltine, Dixie L, Liu, Kevin, Cakana, Andrew, van de Velde, Helgi, Richardson, Paul G

“…Patients with newly diagnosed multiple myeloma who were ineligible for treatment with high-dose chemotherapy plus hematopoietic stem-cell transplantation were…”
Get full text

Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma by MARCUS, Robert, IMRIE, Kevin, WASSNER-FRITSCH, Elisabeth, STEIN, George, SOLAL-CELIGNY, Philippe, CATALANO, John V, DMOSZYNSKA, Anna, RAPOSO, Joao C, OFFNER, Fritz C, GOMEZ-CODINA, José, BELCH, Andrew, CUNNINGHAM, David

“…To compare the long-term outcome of patients with previously untreated follicular lymphoma (FL) needing therapy, after treatment with cyclophosphamide,…”
Get full text

Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma by San Miguel, Jesús F, Schlag, Rudolf, Khuageva, Nuriet K, Dimopoulos, Meletios A, Shpilberg, Ofer, Kropff, Martin, Spicka, Ivan, Petrucci, Maria Teresa, Palumbo, Antonio, Samoilova, Olga S, Dmoszynska, Anna, Abdulkadyrov, Kudrat M, Delforge, Michel, Jiang, Bin, Mateos, Maria-Victoria, Anderson, Kenneth C, Esseltine, Dixie-Lee, Liu, Kevin, Deraedt, William, Cakana, Andrew, van de Velde, Helgi, Richardson, Paul G

“…This final analysis of the phase III VISTA trial (Velcade As Initial Standard Therapy in Multiple Myeloma: Assessment With Melphalan and Prednisone) was…”
Get full text

Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study by HOLOWIECKI, Jerzy, GROSICKI, Sebastian, KLOCZKO, Janusz, JEDRZEJCZAK, Wieslaw W, ZDZIARSKA, Barbara, WARZOCHA, Krzysztof, ZAWILSKA, Krystyna, KOMARNICKI, Mieczysław, KIELBINSKI, Marek, PIATKOWSKA-JAKUBAS, Beata, WIERZBOWSKA, Agnieszka, WACH, Malgorzata, GIEBEL, Sebastian, HAUS, Olga, ROBAK, Tadeusz, KYRCZ-KRZEMIEN, Slawomira, KULICZKOWSKI, Kazimierz, SKOTNICKI, Aleksander B, HELLMANN, Andrzej, SULEK, Kazimierz, DMOSZYNSKA, Anna

“…The goal of this study was to evaluate whether the addition of a purine analog, cladribine or fludarabine, to the standard induction regimen affects the…”
Get full text

Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial by MATEOS, Maria-Victoria, RICHARDSON, Paul G, SAMOILOVA, Olga S, DMOSZYNSKA, Anna, ABDULKADYROV, Kudrat M, SCHOTS, Rik, BIN JIANG, ESSELTINE, Dixie L, LIU, Kevin, CAKANA, Andrew, VAN DE VELDE, Helgi, SAN MIGUEL, Jesús F, SCHLAG, Rudolf, KHUAGEVA, Nuriet K, DIMOPOULOS, Meletios A, SHPILBERG, Ofer, KROPFF, Martin, SPICKA, Ivan, PETRUCCI, Maria T, PALUMBO, Antonio

“…The purpose of this study was to confirm overall survival (OS) and other clinical benefits with bortezomib, melphalan, and prednisone (VMP) versus melphalan…”
Get full text

Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression by Orlowski, Robert Z, Nagler, Arnon, Sonneveld, Pieter, Bladé, Joan, Hajek, Roman, Spencer, Andrew, San Miguel, Jesús, Robak, Tadeusz, Dmoszynska, Anna, Horvath, Noemi, Spicka, Ivan, Sutherland, Heather J, Suvorov, Alexander N, Zhuang, Sen H, Parekh, Trilok, Xiu, Liang, Yuan, Zhilong, Rackoff, Wayne, Harousseau, Jean-Luc

“…This phase III international study compared the efficacy and safety of a combination of pegylated liposomal doxorubicin (PLD) plus bortezomib with bortezomib…”
Get full text

Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide As First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Polish Adult Leukemia Group (PALG-CLL3 Study) by Robak, Tadeusz, Jamroziak, Krzysztof, Gora-Tybor, Joanna, Stella-Holowiecka, Beata, Konopka, Lech, Ceglarek, Bernadetta, Warzocha, Krzysztof, Seferynska, Ilona, Piszcz, Jaroslaw, Calbecka, Malgorzata, Kostyra, Aleksandra, Dwilewicz-Trojaczek, Jadwiga, Dmoszyñska, Anna, Zawilska, Krystyna, Hellmann, Andrzej, Zdunczyk, Andrzej, Potoczek, Stanislaw, Piotrowska, Magdalena, Lewandowski, Krzysztof, Blonski, Jerzy Z

“…PURPOSE Little is known about comparison of the activity of different purine nucleoside analogs in chronic lymphocytic leukemia (CLL). We conducted a…”
Get full text

Alterations in TP53, cyclin D2, c-Myc, p21WAF1/CIP1 and p27KIP1 expression associated with progression in B-CLL by Halina, Antosz, Artur, Paterski, Barbara, Marzec-Kotarska, Joanna, Sajewicz, Anna, Dmoszyńska

“…B-cell chronic lymphocytic leukaemia (B-CLL) originates from B lymphocytes that may differ in the activation level, maturation state or cellular subgroups in…”
Get full text

The VEGF receptor, neuropilin‐1, represents a promising novel target for chronic lymphocytic leukemia patients by Piechnik, Agnieszka, Dmoszynska, Anna, Omiotek, Marcin, Mlak, Radosław, Kowal, Małgorzata, Stilgenbauer, Stephan, Bullinger, Lars, Giannopoulos, Krzysztof

“…Angiogenesis has been shown to substantially contribute to the progression of chronic lymphocytic leukemia (CLL). Neuropilin‐1 (NRP1) represents a receptor for…”
Get full text

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia by Gambacorti‐Passerini, Carlo, Cortes, Jorge E., Lipton, Jeff H., Dmoszynska, Anna, Wong, Raymond S., Rossiev, Victor, Pavlov, Dmitri, Gogat Marchant, Karin, Duvillié, Ladan, Khattry, Navin, Kantarjian, Hagop M., Brümmendorf, Tim H.

“…Bosutinib, an orally active, Src/Abl tyrosine kinase inhibitor, has demonstrated clinical activity and acceptable tolerability in chronic phase chronic myeloid…”
Get full text

Circulating microenvironment of CLL: Are nurse-like cells related to tumor-associated macrophages? by Filip, Agata A., Ciseł, Bogumiła, Koczkodaj, Dorota, Wąsik-Szczepanek, Ewa, Piersiak, Tomasz, Dmoszyńska, Anna

“…B-cell chronic lymphocytic leukemia (B-CLL) is one of the most common hematologic malignancies in Western countries. Accumulation of leukemic lymphocytes in…”
Get full text

Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia by Grzywnowicz, Maciej, Zaleska, Joanna, Mertens, Daniel, Tomczak, Waldemar, Wlasiuk, Paulina, Kosior, Kamila, Piechnik, Agnieszka, Bojarska-Junak, Agnieszka, Dmoszynska, Anna, Giannopoulos, Krzysztof

“…Programmed death-1 (PD-1) is an immunoreceptor predominantly expressed on exhausted T cells, which through an interaction with its ligand (PD-L1), controls…”
Get full text

Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma by LUDWIG, Heinz, VITERBO, Luisa, ESTEVES, Graca, STOPPA, Anne Marie, ROBINSON, Don, RICCI, Deborah, CAKANA, Andrew, ENNY, Christopher, HUAIBAO FENG, DE VELDE, Helgi Van, HAROUSSEAU, Jean-Luc, GREIL, Richard, MASSZI, Tamas, SPICKA, Ivan, SHPILBERG, Ofer, HAJEK, Roman, DMOSZYNSKA, Anna, PAIVA, Bruno, VIDRIALES, María-Belén

“…Bortezomib-thalidomide-dexamethasone (VTD) is an effective induction therapy in multiple myeloma (MM). This phase II, noncomparative study sought to determine…”
Get full text

Altered plasma fibrin clot properties and fibrinolysis in patients with multiple myeloma by Undas, Anetta, Zubkiewicz-Usnarska, Lidia, Helbig, Grzegorz, Woszczyk, Dariusz, Kozińska, Justyna, Dmoszyńska, Anna, Podolak-Dawidziak, Maria, Kuliczkowski, Kazimierz

“…Background Multiple myeloma (MM) is associated with increased risk of venous and arterial thromboembolism. Formation of denser and poorly lysable fibrin clots…”
Get full text

Total expression of HLA-G and TLR-9 in chronic lymphocytic leukemia patients by Własiuk, Paulina, Tomczak, Waldemar, Zając, Małgorzata, Dmoszyńska, Anna, Giannopoulos, Krzysztof

“…Abstract Suppressed immune status facilitates immune escape mechanisms that allow chronic lymphocytic leukemia cells to proliferate and expand. The expression…”
Get full text